OBJECTIVE: Our understanding of the etiology and pathogenesis of neuropsychiatric involvement in primary Sjögren's syndrome (SS) is incomplete. In systemic lupus erythematosus, it has been reported that antibodies directed against N-methyl-D-aspartate receptor subtype NR2 (anti-NR2) interfere with memory and learning function, as well as mood. This has not been investigated in primary SS; however, the present study was undertaken to advance our understanding of neuropsychiatric involvement in this disease. METHODS: Sixty-six patients with primary SS and 66 age- and sex-matched healthy control subjects underwent clinical examination and neuropsychological evaluation. Anti-NR2 antibodies were measured in serum and cerebrospinal fluid. Hippocampus volume was estimated using software extensions to SPM5. RESULTS: Patients with primary SS had smaller hippocampi than healthy subjects (mean ± SD 8.15 ± 0.98 cm(3) versus 8.49 ± 0.88 cm(3); P = 0.01). In patients with primary SS, anti-NR2 antibodies in cerebrospinal fluid were associated with a worse performance in 8 of 10 memory and learning tests, and anti-NR2 antibodies in serum were associated with a worse performance in 6 of those same tests. In addition, a higher proportion of patients with depression than patients without depression had serum anti-NR2 antibody levels above the cutoff value. CONCLUSION: Results of this study indicate that anti-NR2 antibodies may represent one of the pathogenetic mechanisms for cognitive disturbances and mood disorders in patients with primary SS.
OBJECTIVE: Our understanding of the etiology and pathogenesis of neuropsychiatric involvement in primary Sjögren's syndrome (SS) is incomplete. In systemic lupus erythematosus, it has been reported that antibodies directed against N-methyl-D-aspartate receptor subtype NR2 (anti-NR2) interfere with memory and learning function, as well as mood. This has not been investigated in primary SS; however, the present study was undertaken to advance our understanding of neuropsychiatric involvement in this disease. METHODS: Sixty-six patients with primary SS and 66 age- and sex-matched healthy control subjects underwent clinical examination and neuropsychological evaluation. Anti-NR2 antibodies were measured in serum and cerebrospinal fluid. Hippocampus volume was estimated using software extensions to SPM5. RESULTS:Patients with primary SS had smaller hippocampi than healthy subjects (mean ± SD 8.15 ± 0.98 cm(3) versus 8.49 ± 0.88 cm(3); P = 0.01). In patients with primary SS, anti-NR2 antibodies in cerebrospinal fluid were associated with a worse performance in 8 of 10 memory and learning tests, and anti-NR2 antibodies in serum were associated with a worse performance in 6 of those same tests. In addition, a higher proportion of patients with depression than patients without depression had serum anti-NR2 antibody levels above the cutoff value. CONCLUSION: Results of this study indicate that anti-NR2 antibodies may represent one of the pathogenetic mechanisms for cognitive disturbances and mood disorders in patients with primary SS.
Authors: Maria Boge Lauvsnes; Henrik Zetterberg; Kaj Blennow; Jan Terje Kvaløy; Anne Bolette Tjensvoll; Stian Maroni; Mona K Beyer; Ole Jacob Greve; Ingeborg Kvivik; Guido Alves; Lasse Gunnar Gøransson; Erna Harboe; Shunsei Hirohata; Roald Omdal Journal: J Neurol Date: 2021-11-20 Impact factor: 4.849
Authors: Sandrine Indart; Jacques Hugon; Pierre Jean Guillausseau; Alice Gilbert; Julien Dumurgier; Claire Paquet; Damien Sène Journal: Medicine (Baltimore) Date: 2017-04 Impact factor: 1.889
Authors: Tabea Seeliger; Lena Jacobsen; Merle Hendel; Lena Bönig; Nils K Kristian Prenzler; Thea Thiele; Diana Ernst; Torsten Witte; Martin Stangel; Bruno Kopp; Thomas Skripuletz Journal: Ann Clin Transl Neurol Date: 2020-07-06 Impact factor: 4.511
Authors: Anne B Tjensvoll; Maria B Lauvsnes; Henrik Zetterberg; Jan T Kvaløy; Ingeborg Kvivik; Stian S Maroni; Ole J Greve; Mona K Beyer; Shunsei Hirohata; Chaim Putterman; Guido Alves; Erna Harboe; Kaj Blennow; Lasse G Gøransson; Roald Omdal Journal: J Neurol Date: 2020-10-30 Impact factor: 4.849